FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer
Clinical trial NCT05304962 · RECRUITING
Trial details
- NCT number
- NCT05304962
- Sponsor
- Regor Pharmaceuticals Inc.
- Status
- RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-03-04
- Primary completion
- 2026-12-30
- Enrollment
- 64
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.